GLOBE MEDICLINE: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
GLOBE MEDICLINE
Largest movements
- Receivables within one year -€402
down €402 (-5.3%), from €7,559 to €7,157
- Profit (loss) carried forward -€2,093
down €2,093 (-6.9%), from -€30,166 to -€32,259
- Short-term financial debts +€1,398
up €1,398 (+11.9%), from €11,800 to €13,198
- Trade debts +€653
up €653 (+53.5%), from €1,220 to €1,872
- Accrued charges and deferred income -€390
no longer reported in 2024 (was €390)
- Gross operating margin +€1,178
up €1,178, from -€909 to €269
- Financial charges -€264
down €264 (-11.8%), from €2,239 to €1,975
From the 2023 result to the 2024 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2023 and 2024 balance sheets and the 2024 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2023 | 2024 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €8,241 | €7,837 | -€404 | -4.9% |
| Current assets | 29/58 | €8,241 | €7,837 | -€404 | -4.9% |
| Amounts receivable within one year | 40/41 | €7,559 | €7,157 | -€402 | -5.3% |
| Other amounts receivable | 41 | €7,559 | €7,157 | -€402 | -5.3% |
| Cash at bank and in hand | 54/58 | €682 | €680 | -€2 | -0.3% |
| Total equity and liabilities | 10/49 | €8,241 | €7,837 | -€404 | -4.9% |
| Equity | 10/15 | -€6,707 | -€8,800 | -€2,093 | -31.2% |
| Contributions | 10/11 | €18,592 | €18,592 | = | 0.0% |
| Reserves | 13 | €4,866 | €4,866 | = | 0.0% |
| Distributable reserves | 133 | €4,866 | €4,866 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€30,166 | -€32,259 | -€2,093 | -6.9% |
| Amounts payable | 17/49 | €14,949 | €16,638 | +€1,689 | +11.3% |
| Amounts payable within one year | 42/48 | €14,559 | €16,638 | +€2,079 | +14.3% |
| Financial debts | 43 | €11,800 | €13,198 | +€1,398 | +11.9% |
| Credit institutions | 430/8 | €11,800 | €13,198 | +€1,398 | +11.9% |
| Trade debts | 44 | €1,220 | €1,872 | +€653 | +53.5% |
| Suppliers | 440/4 | €1,220 | €1,872 | +€653 | +53.5% |
| Other amounts payable | 47/48 | €1,539 | €1,567 | +€28 | +1.8% |
| Accrued charges and deferred income | 492/3 | €390 | - | -€390 | |
| Other operating charges | 640/8 | €384 | €387 | +€3 | +0.8% |
| Gross operating margin | 9900 | -€909 | €269 | +€1,178 | |
| Operating profit (loss) | 9901 | -€1,294 | -€118 | +€1,175 | +90.9% |
| Financial charges | 65/66B | €2,239 | €1,975 | -€264 | -11.8% |
| Recurring financial charges | 65 | €2,239 | €1,975 | -€264 | -11.8% |
| Profit (loss) for the period before taxes | 9903 | -€3,532 | -€2,093 | +€1,439 | +40.7% |
| Profit (loss) for the period | 9904 | -€3,532 | -€2,093 | +€1,439 | +40.7% |
| Profit (loss) for the period to be appropriated | 9905 | -€3,532 | -€2,093 | +€1,439 | +40.7% |
Source: filed annual accounts (NBB), financial years ended 31 December 2023 and 31 December 2024. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 22 October 2026 via checked.be.